Duloxetine in the prevention of depressive recurrences: A randomized, double-blind, placebo-controlled trial

Journal of Clinical Psychiatry

Volumn 70, Issue 5, 2009, Pages 706-716

  Perahia, David G S ^a,b   Maina, Giuseppe ^c   Thase, Michael E ^d   Spann, Melissa E ^a   Wang, Fujun ^a   Walker, Daniel J ^a   Detke, Michael J ^a,e,f  

^a ELI LILLY AND COMPANY   (United States)

^b Gordon Hospital   (United Kingdom)

^c UNIVERSITY OF TURIN   (Italy)

^d UNIVERSITY OF PITTSBURGH   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DULOXETINE; PLACEBO;

ABSCESS; ACUTE PANCREATITIS; ADULT; ARTICLE; BACKACHE; BACTERIAL SKIN DISEASE; CHLAMYDIAL PNEUMONIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVULSION; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE SEVERITY; DIVERTICULOSIS; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOCARDITIS; FATIGUE; FEMALE; FOREIGN BODY REACTION; HAMILTON SCALE; HEAD INJURY; HEADACHE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERHIDROSIS; HYPERTENSION; HYPERTENSIVE CRISIS; HYPOTENSION; INFLUENZA; INSOMNIA; INTERVERTEBRAL DISK HERNIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MIGRAINE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; PYELONEPHRITIS; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RHINOPHARYNGITIS; SOMATIZATION; STAPHYLOCOCCUS INFECTION; SUICIDE; SUICIDE ATTEMPT; THROAT TIGHTNESS; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; TREATMENT RESPONSE; UTERUS MYOMA; VOMITING; XEROSTOMIA;

DEPRESSIVE DISORDER, MAJOR; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; PREVALENCE; RECURRENCE; SEROTONIN UPTAKE INHIBITORS; SEX DISTRIBUTION; THIOPHENES;

EID: 67049142359     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.08m04756     Document Type: Article

References (45)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994
2. Mueller TI, Leon AC, Keller MB, et al. Recurrence after recovery from major depressive disorder during 15 years of observational follow-up. Am J Psychiatry 1999;156(7):1000-1006 (Pubitemid 29302790)
3. Kessing LV. Recurrence in affective disorder, 2: effect of age and gender. Br J Psychiatry 1998;172:29-34
4. Solomon DA, Keller MB, Leon AC, et al. Multiple recurrences of major depressive disorder. Am J Psychiatry 2000;157(2):229-233 (Pubitemid 30080902)
5. Melartin TK, Rytsala HJ, Leskela US, et al. Severity and comorbidity predict episode duration and recurrence of DSM-IV major depressive disorder. J Clin Psychiatry 2004;65(6):810-819
6. Judd LL, Akiskal HS, Maser JD, et al. Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Disord 1998;50(2-3):97-108 (Pubitemid 28551779)
7. Katon WJ, Fan M-Y, Lin EHB, et al. Depressive symptom deterioration in a large primary care-based elderly cohort. Am J Geriatr Psychiatry 2006;14(3):246-254
8. Lin EH, Katon WJ, VonKorff M, et al. Relapse of depression in primary care: rate and clinical predictors. Arch Fam Med 1998;7(5):443-449 (Pubitemid 128435151)
9. Kupfer DJ, Frank E, Perel JM, et al. Five-year outcome for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1992;49(10):769-773
10. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Major Depressive Disorder (revision). Am J Psychiatry 2000;157(suppl 4):1-45 (Pubitemid 30193855)
11. Thase ME. Preventing relapse and recurrence of depression: a brief review of therapeutic options. CNS Spectr 2006;11(suppl 15):12-21 (Pubitemid 46012530)
12. Kupfer DJ. Long-term treatment of depression. J Clin Psychiatry 1991;52(suppl):28-34
13. Hirschfeld RM. Antidepressants in long-term therapy: a review of tricyclic antidepressants and selective serotonin reuptake inhibitors. Acta Psychiatr Scand 2000;101(S403):35-38 (Pubitemid 30691134)
14. Frank E, Kupfer DJ, Perel JM, et al. Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1990;47(12):1093-1099
15. Gilaberte I, Montejo AL, de la Gandara J, et al. Fluoxetine in the prevention of depressive recurrences: a double-blind study. J Clin Psychopharmacol 2001;21(4):417-424 (Pubitemid 32673031)
16. Terra JL, Montgomery SA. Fluvoxamine prevents recurrence of depression: results of a long-term, double-blind, placebo-controlled study. Int Clin Psychopharmacol 1998;13(2):55-62 (Pubitemid 28218515)
17. Franchini L, Gasperini M, Perez J, et al. Dose-response efficacy of paroxetine in preventing depressive recurrences: a randomized, double-blind study. J Clin Psychiatry 1998;59(5):229-232 (Pubitemid 28274606)
18. Lepine JP, Caillard V, Bisserbe JC, et al. A randomized, placebo-controlled trial of sertraline for prophylactic treatment of highly recurrent major depressive disorder. Am J Psychiatry 2004;161(5):836-842 (Pubitemid 38625336)
19. Kocsis JH, Thase ME, Trivedi MH, et al. Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT study. J Clin Psychiatry 2007;68(7):1014-1023 (Pubitemid 47340320)
20. Keller MB, Trivedi MH, Thase ME, et al. The prevention of recurrent episodes of depression with venlafaxine for two years (PREVENT) study: outcomes from the 2-year and combined maintenance phases. J Clin Psychiatry 2007;68(8):1246-1256 (Pubitemid 47395628)
21. Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry 2002;63(4):308-315 (Pubitemid 34456358)
22. Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatr Res 2002;36(6):383-390 (Pubitemid 35254112)
23. Perahia DG, Gilaberte I, Wang F, et al. Duloxetine in the prevention of relapse of major depressive disorder: a double-blind, placebo-controlled study. Br J Psychiatry 2006;188:346-353
24. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
25. Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised. US Department of Health, Education, and Welfare publication (ADM). Rockville, MD: National Institute of Mental Health; 1976:76-338
26. Sheehan DV, Lecrubier Y, et al. Mini-International Neuropsychiatric Interview (MINI). Tampa, Fla: University of South Florida, Institute for Research in Psychiatry, and Paris, France: INSERM-Hopital de la Salpetriere; 1994
27. Faries D, Herrera J, Rayamajhi J, et al. The responsiveness of the Hamilton Depression Rating Scale. J Psychiatr Res 2000;34(1):3-10 (Pubitemid 30006935)
28. Kellner R. A symptom questionnaire. J Clin Psychiatry 1987;48(7):268-274 (Pubitemid 17108403)
29. DeLoach LJ, Higgins MS, Caplan AB, et al. The Visual Analog Scale in the immediate postoperative period: intrasubject variability and correlation with a numeric scale. Anesth Analg 1998;86(1):102-106 (Pubitemid 28040099)
30. Ware JE, Snow KK, Kosinski M, et al. SF-36 Health Survey Manual and Interpretation Guide. Boston, MA: The Health Institute, New England Medical Center; 1993
31. Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. Int Clin Psychopharmacol 1996;11(suppl 3):89-95 (Pubitemid 26373761)
32. Broadhead WE, Blazer DG, George LK, et al. Depression, disability days, and days lost from work in a prospective epidemiologic survey. JAMA 1990;264(19):2524-2528
33. Revicki DA, Irwin D, Reblando J, et al. The accuracy of self-reported disability days. Med Care 1994;32(4):401-404
34. McGahuey CA, Gelenberg AJ, Laukes CA, et al. The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Ther 2000;26(1):25-40 (Pubitemid 30046590)
35. Kornstein SG, Bose A, Li D, et al. Escitalopram maintenance treatment for prevention of recurrent depression: a randomized, placebo-controlled trial. J Clin Psychiatry 2006;67(11):1767-1775 (Pubitemid 44955159)
36. Montgomery SA, Entsuah R, Hackett D, et al. Venlafaxine versus placebo in the preventive treatment of recurrent major depression. J Clin Psychiatry 2004;65(3):328-336
37. Montgomery SA, Dufour H, Brion S, et al. The prophylactic efficacy of fluoxetine in unipolar depression. Br J Psychiatry Suppl 1988;(3):69-76 (Pubitemid 18231716)
38. Gahimer J, Wernicke J, Yalcin I, et al. A retrospective pooled analysis of duloxetine safety in 23,983 subjects. Curr Med Res Opin 2007;23(1):175-184 (Pubitemid 46191681)
39. Greist J, McNamara RK, Mallinckrodt CH, et al. Incidence and duration of antidepressant-induced nausea: duloxetine compared with paroxetine and fluoxetine. Clin Ther 2004;26:1446-1455 (Pubitemid 39582713)
40. Davidson JR, Wittchen HU, Llorca PM, et al. Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: a double-blind placebo-controlled trial. Eur Neuropsychopharmacol 2008;18(9):673-681
41. Papakostas GI. Tolerability of modern antidepressants. J Clin Psychiatry 2008;69(suppl E1):8-13
42. Hu XH, Bull SA, Hunkeler EM, et al. Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report versus physician estimate. J Clin Psychiatry 2004;65(7):959-965
43. Baldwin DS. Depression and sexual dysfunction. Br Med Bull 2001;57:81-99
44. Ferguson JM. The effects of antidepressants on sexual functioning in depressed patients: a review. J Clin Psychiatry 2001;62(suppl 3):22-34 (Pubitemid 32164677)
45. Delgado PL, Brannan SK, Mallinckrodt CH, et al. Sexual functioning assessed in 4 double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder. J Clin Psychiatry 2005;66(6):686-692 (Pubitemid 40942413)